List of Excipients in Branded Drug REXULTI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Otsuka America Pharmaceutical Inc	REXULTI	brexpiprazole	59148-035	CELLULOSE, MICROCRYSTALLINE
Otsuka America Pharmaceutical Inc	REXULTI	brexpiprazole	59148-035	FERRIC OXIDE RED
Otsuka America Pharmaceutical Inc	REXULTI	brexpiprazole	59148-035	FERRIC OXIDE YELLOW
Otsuka America Pharmaceutical Inc	REXULTI	brexpiprazole	59148-035	FERROSOFERRIC OXIDE
Otsuka America Pharmaceutical Inc	REXULTI	brexpiprazole	59148-035	HYDROXYPROPYL CELLULOSE

REXULTI Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

REXULTI, the brand name for brexpiprazole, is an immediate-release oral tablet marketed by Otsuka Pharmaceutical and Lundbeck. Its excipient system is conventional but commercially relevant: lactose, starch, microcrystalline cellulose, polymeric binders, a disintegrant, magnesium stearate, and iron-oxide colorants. The principal opportunities are generic-tablet development, differentiated oral delivery, excipient-risk management, and lifecycle products for schizophrenia, adjunctive major depressive disorder, and agitation associated with Alzheimer’s dementia.

The strongest near-term commercial strategy is a low-risk, bioequivalent tablet that matches REXULTI’s dissolution and impurity profile without copying nonessential color or processing choices. A liquid, orally disintegrating, sprinkle, or modified-release product would offer greater differentiation but would face higher clinical, CMC, and intellectual-property risk.

What excipients are used in REXULTI tablets?

REXULTI tablets use a conventional solid oral formulation platform. The FDA prescribing information identifies the following inactive ingredients:

Excipient	Primary formulation function	Commercial relevance
Lactose monohydrate	Diluent and tablet bulking agent	Relevant for lactose intolerance, supplier qualification, and generic substitution
Corn starch	Diluent and disintegration support	Supports tablet breakup and processability
Microcrystalline cellulose	Filler, dry binder, and compression aid	Critical to hardness, friability, and tablet tensile strength
Hydroxypropyl cellulose	Binder	Controls granule or powder cohesion
Low-substituted hydroxypropyl cellulose	Disintegrant	Supports rapid tablet breakup
Magnesium stearate	Lubricant	Affects ejection force, wetting, and dissolution
Ferric oxide colorants	Tablet identification and strength differentiation	Important for appearance, manufacturing controls, and medication-error reduction

The precise strength-specific colorant composition and quantitative formula should be taken from the applicable FDA labeling and manufacturing documentation rather than inferred from tablet appearance. The commercial product is supplied in multiple strengths, which increases the value of color and imprint controls for dose differentiation. (U.S. Food and Drug Administration [FDA], 2023a)

How does the REXULTI excipient system affect generic development?

A generic developer does not need to duplicate every inactive ingredient. The ANDA must demonstrate pharmaceutical equivalence and bioequivalence, comply with applicable inactive-ingredient requirements, and establish acceptable quality performance. In practice, excipient selection must preserve dissolution, assay uniformity, stability, tablet mechanical properties, and impurity control.

Lactose and starch platform

Lactose monohydrate and corn starch are widely available and generally economical. They reduce formulation cost and support conventional tablet manufacturing. Their main development risks are variability in particle size, moisture, bulk density, and supplier grade.

A developer changing lactose grade, starch source, or particle-size distribution may alter:

• Blend uniformity
• Compression force
• Tablet porosity
• Disintegration time
• Dissolution under discriminatory conditions
• Moisture-driven degradation

Supplier qualification is therefore a commercial issue, not only a quality function. Dual sourcing can reduce supply risk, but material changes may require comparability work and process revalidation.

Microcrystalline cellulose and hydroxypropyl cellulose

Microcrystalline cellulose provides compression strength and can reduce dependence on high compression force. Hydroxypropyl cellulose helps bind the powder blend or granules. The balance between binder level and disintegrant performance is important because excessive binding can slow tablet breakup and dissolution.

The formulation is likely to be sensitive to:

• Granulation endpoint
• Binder distribution
• Lubrication time
• Compression force
• Tablet porosity
• Excipient moisture

Those variables are potential manufacturing barriers even when the qualitative excipient list is simple.

Magnesium stearate

Magnesium stearate is a low-cost, widely used lubricant, but over-lubrication can reduce powder wettability and slow dissolution. A generic product that matches assay but shows slower dissolution may face additional development work, particularly if the reference product has a narrow dissolution profile.

Lubricant optimization can create a practical design-around opportunity. A developer may use a different magnesium stearate grade, a reduced concentration, or another lubricant, subject to compatibility, process, and regulatory requirements.

What formulation patents protect REXULTI?

The core protection for brexpiprazole has historically centered on composition-of-matter and therapeutic-use patents rather than a complex excipient platform. The earliest U.S. patent family associated with brexpiprazole is U.S. Patent No. 7,888,362, covering quinoline derivatives that include brexpiprazole-related chemical matter. Patent term, listed expiration, pediatric extension, and any terminal disclaimer must be confirmed against the current FDA Orange Book and USPTO records. (U.S. Patent and Trademark Office [USPTO], 2011; FDA, 2024a)

For commercial formulation planning, the relevant distinction is:

Protection category	Relevance to an excipient strategy
Composition-of-matter patent	Can block commercial brexpiprazole regardless of excipient selection until expiration
Method-of-use patent	Can restrict labeled use, including specific patient populations or disease indications
Formulation patent	Can restrict a particular dosage form, release profile, salt, particle system, or excipient combination
Manufacturing patent	Can create process risk even when the finished tablet uses different excipients
Regulatory exclusivity	Can delay approval independent of patent status

Changing lactose to mannitol, replacing starch, or using a different binder does not avoid a composition patent. Excipient substitution becomes legally meaningful only when the relevant protection is limited to a formulation, process, or specific delivery system.

When does REXULTI lose exclusivity?

REXULTI’s U.S. market protection depends on several separate dates rather than one universal loss-of-exclusivity date.

Milestone	Status
FDA approval for schizophrenia	2015
FDA approval as adjunctive treatment for major depressive disorder	2015
FDA approval for agitation associated with Alzheimer’s dementia	2023
New chemical entity exclusivity	Expired
Pediatric exclusivity	Must be assessed against the current Orange Book record
Patent protection	Depends on the applicable patent family, claim scope, and term adjustment
Generic entry	Depends on ANDA approval, patent certifications, litigation, settlements, and any court-imposed stay

FDA approval does not mean that all indications have the same practical generic-entry risk. A generic applicant may challenge listed patents through a Paragraph IV certification while avoiding a method-of-use patent through a section viii statement and labeling carve-out, if the product can lawfully be marketed for the remaining indications. (FDA, 2024a; FDA, 2024b)

What is the Orange Book status of REXULTI?

The Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved REXULTI products. It should be reviewed by product strength, dosage form, patent number, patent expiration, and use code.

The relevant regulatory questions are:

1. Which patents are listed against the brexpiprazole tablet?
2. Which use codes correspond to schizophrenia, depression, or Alzheimer’s-related agitation?
3. Are any patents eligible for a section viii carve-out?
4. Is pediatric exclusivity attached to a listed patent?
5. Has an ANDA applicant submitted a Paragraph IV certification?
6. Has the NDA holder filed suit within the statutory 45-day period?
7. Has a settlement authorized an earlier generic launch?

A commercial diligence review should not treat a patent expiration date alone as the launch date. A 30-month stay, court decision, settlement license, pediatric extension, or regulatory deficiency can materially change timing. (FDA, 2024a)

Which companies are challenging REXULTI?

Public generic competition should be assessed through FDA ANDA records, Paragraph IV litigation databases, PACER, and Orange Book updates. A listed patent challenge may not become visible in marketing terms until litigation, settlement, or ANDA approval is disclosed.

The likely competitive field includes large generic manufacturers with CNS infrastructure, such as Teva, Sandoz, Viatris, Amneal, Lupin, Dr. Reddy’s, and Sun Pharma. That list identifies potential market participants, not confirmed REXULTI challengers.

For investors and licensors, the key indicators are:

• First Paragraph IV filing
• 180-day exclusivity eligibility
• Number of ANDAs referencing REXULTI
• Litigation dismissal or settlement
• Tentative approval
• Product-specific manufacturing capacity
• Commercial launch timing after patent resolution

How strong is the REXULTI patent estate?

The estate has meaningful value because brexpiprazole is a branded small molecule with several approved uses and a commercially established tablet. Its strength is greater against direct generic substitution than against differentiated delivery products.

Stronger protection

Composition-of-matter claims generally provide the broadest protection. They apply regardless of whether a competitor uses lactose, mannitol, a liquid vehicle, or an orally disintegrating platform, subject to claim scope and patent validity.

Approved-use patents can remain commercially important after composition protection weakens. The 2023 Alzheimer’s agitation approval expanded the product’s addressable market and created potential value in indication-specific patent claims and regulatory exclusivity.

Weaker or more contestable protection

Excipient-specific claims are narrower. They can be challenged through:

• Alternative excipients
• Different ratios
• Different processing conditions
• Noninfringing dissolution profiles
• Different tablet architecture
• Invalidity arguments based on obviousness or lack of enablement

A formulation patent is most valuable when it protects a clinically meaningful property, such as improved stability, reduced variability, enhanced dissolution, or a differentiated administration method.

What excipient opportunities exist for REXULTI generics?

1. Direct bioequivalent tablet

The lowest-risk opportunity is a conventional tablet using the reference product as a performance benchmark. A developer can preserve the general excipient architecture while optimizing supplier grades, compression, lubrication, and disintegration.

This approach minimizes clinical risk and supports a standard ANDA pathway. The trade-off is limited differentiation and greater price competition after launch.

2. Lactose-free tablet

A lactose-free formulation using mannitol, dibasic calcium phosphate, or another suitable diluent could address patient and manufacturing preferences. The product would need to maintain tablet strength, dissolution, stability, and acceptable inactive-ingredient exposure.

A lactose-free positioning has commercial value only if it produces a meaningful patient, pharmacy, or procurement advantage. It does not by itself create regulatory exclusivity.

3. Orally disintegrating tablet

An orally disintegrating brexpiprazole tablet could target patients with swallowing difficulty, poor adherence, caregiver administration needs, or psychiatric decompensation. Potential excipients include mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and taste-masking agents.

The development burden is higher because the sponsor must address:

• Rapid disintegration
• Taste and mouthfeel
• Dose uniformity at low strength
• Moisture protection
• Packaging performance
• Stability
• Human factors
• Potentially different bioequivalence requirements

The product could support a 505(b)(2) strategy if it makes a clinically meaningful change, but the regulatory pathway would depend on the formulation, claims, and reference product.

4. Oral liquid or sprinkle product

A liquid or sprinkle formulation could improve administration for patients unable to swallow tablets. Brexpiprazole’s physicochemical properties, dose accuracy, suspension stability, preservative system, and taste would determine feasibility.

This is a higher-value but higher-risk opportunity. It may require additional clinical or bridging work and could encounter method-of-use or formulation patent claims.

5. Modified-release delivery

Modified-release brexpiprazole could seek longer exposure or reduced dosing frequency. The commercial proposition is weaker than an orally disintegrating or liquid product because REXULTI is already orally administered and its clinical use does not inherently require extended release.

A modified-release product would require pharmacokinetic, dose-titration, food-effect, safety, and bioequivalence development. It should be viewed as a lifecycle product rather than a simple generic substitution.

What manufacturing and IP barriers affect REXULTI excipient opportunities?

The main technical barriers are low-dose content uniformity, dissolution control, powder segregation, lubrication sensitivity, and stability. Brexpiprazole tablets include a 0.25 mg strength, making blend uniformity and sampling strategy particularly important.

Manufacturing controls should focus on:

• Geometric dilution or engineered blending for low-dose strengths
• Excipient particle-size distribution
• Blend segregation during transfer
• Compression-force control
• Magnesium stearate mixing time
• Tablet weight and hardness
• Dissolution across multiple media
• Moisture and temperature exposure
• Cleaning validation for potent CNS-active material

The main IP barrier is the active ingredient and use claims, not the presence of ordinary excipients. A formulation redesign can reduce risk only after claim charts compare the proposed product with every relevant patent claim.

How does REXULTI compare with competing antipsychotic products?

Product	Active ingredient	Dosage-form opportunity	Biosimilar risk	Generic substitution profile
REXULTI	Brexpiprazole	ODT, liquid, sprinkle, modified release	None; small molecule	Conventional tablet ANDA competition
Abilify	Aripiprazole	Tablets, ODT, oral solution, long-acting injections	None	Mature generic competition
Vraylar	Cariprazine	Capsule and potential differentiated oral delivery	None	Formulation and indication protection remain relevant
Seroquel XR	Quetiapine extended release	Modified-release products	None	Release-control technology is central
Latuda	Lurasidone	Immediate-release tablet	None	Food-effect and formulation performance are important

REXULTI’s commercial advantage is an established branded product with multiple indications. Its formulation opportunity is less differentiated than long-acting injectable antipsychotics but more open to patient-oriented oral delivery products.

What revenue exposure exists for REXULTI?

REXULTI has exposure to three commercial markets:

1. Schizophrenia
2. Adjunctive major depressive disorder
3. Agitation associated with Alzheimer’s dementia

The Alzheimer’s indication materially expands the addressable population but also increases scrutiny of mortality, cerebrovascular events, sedation, falls, and caregiver administration. FDA labeling carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis and states that REXULTI is not approved for treating dementia-related psychosis except for agitation associated with Alzheimer’s dementia. (FDA, 2023a)

For generic entrants, the Alzheimer’s indication can increase demand but complicate labeling strategy. A carve-out that excludes a protected use may reduce the commercial opportunity, while a full label may increase patent exposure.

What regulatory status does REXULTI have?

REXULTI is FDA-approved as an oral tablet for adults with schizophrenia, as adjunctive therapy for major depressive disorder, and for agitation associated with Alzheimer’s dementia. It is not a biologic and does not require a biosimilar pathway. Generic competitors would generally pursue an ANDA for the listed tablet strengths, while differentiated dosage forms may require a 505(b)(2) application or a new drug application.

No biosimilar risk exists because brexpiprazole is a chemically synthesized small molecule. The relevant competitive risks are ANDA filings, Paragraph IV challenges, authorized generic arrangements, formulation redesigns, and indication-specific patent enforcement.

Key Takeaways

• REXULTI uses a conventional tablet excipient platform built around lactose, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, and iron oxides.
• The highest-probability generic opportunity is a conventional bioequivalent tablet with controlled dissolution and low-dose uniformity.
• Lactose-free, orally disintegrating, liquid, sprinkle, and modified-release products offer greater differentiation but higher regulatory and technical risk.
• Excipient substitution does not avoid composition-of-matter patents.
• Orange Book use codes, Paragraph IV certifications, litigation, settlements, pediatric exclusivity, and patent-term adjustments determine actual generic-entry timing.
• REXULTI has no biosimilar risk because brexpiprazole is a small molecule.
• The 2023 Alzheimer’s agitation approval expands commercial value but increases safety, labeling, and indication-specific patent considerations.
• The most defensible lifecycle opportunity is a patient-oriented delivery system supported by measurable adherence or administration benefits.

FAQs

Can a generic REXULTI use different excipients?

Yes. A generic may use different inactive ingredients if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and labeling. The formulation must still reproduce critical performance attributes.

Is REXULTI suitable for an orally disintegrating tablet?

Yes, technically. An orally disintegrating product could address swallowing and caregiver-administration needs, but taste masking, moisture control, low-dose uniformity, dissolution, and regulatory bridging would be central development issues.

Does a lactose-free REXULTI automatically avoid patent infringement?

No. Replacing lactose does not avoid composition-of-matter or broad method-of-use claims. It may matter only against a narrow formulation claim that requires lactose or a specific excipient combination.

Can a generic launch for schizophrenia while excluding Alzheimer’s agitation?

Potentially. A section viii labeling carve-out may be available for a patented method of use, but the feasibility depends on the Orange Book use code, approved labeling, claim scope, and FDA acceptance of the proposed label.

Is a liquid brexpiprazole product commercially attractive?

It may be attractive for patients with swallowing difficulty and caregiver-administered treatment. Its value depends on formulation stability, dose accuracy, taste, packaging, regulatory pathway, patent clearance, and whether the product produces sufficient clinical or adherence differentiation.

References

1. U.S. Food and Drug Administration. (2023a). REXULTI (brexpiprazole) prescribing information.
2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024b). Abbreviated new drug application regulations and patent certification requirements.
4. U.S. Patent and Trademark Office. (2011). U.S. Patent No. 7,888,362, quinoline derivatives.
5. U.S. Food and Drug Administration. (2023b). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules.